


# Hospira's SIP Pipeline

**40 Molecules in the Pipeline at December 31, 2008\***

*Local Market Value\*\* of \$14 Billion for Small-Molecule Compounds*

19 pre-dossier molecules

21 molecules submitted for regulatory approval;  
Estimated LMV\*\* of small molecules ≈ \$8.5 billion




\* The 40 molecules in the product pipeline includes biogenics; the LMV does not include biogenics

\*\*LMV (local market value) refers to the 2007 annual sales of equivalent products already being sold in the market, whether patented or generic. LMV is not a forecast of Hospira's expected sales revenue.

# Pipeline Therapeutic Class

***Based on \$ LMV, Excludes Biogenerics***



\* Represents the 2007 Local Market Value (LMV) of the small-molecule compounds in Hospira's product pipeline at 12/31/08; excludes biogenerics.

\* Local market value refers to the annual sales of equivalent products already being sold in the market, whether patented or generic. LMV is not a forecast of Hospira's expected sales revenue.